Mylan Loses Bid To Dismiss MS Drug Patent Suit

Law360, New York (August 29, 2011, 7:17 PM EDT) -- Mylan Pharmaceuticals Inc. lost a bid Monday to dismiss Teva Pharmaceutical Industries Ltd.'s patent suit over the multiple-sclerosis drug Copaxone when a New York federal judge found that the drug's patents are valid.

U.S. District Judge Barbara S. Jones rejected Mylan's argument that the claims in Teva's Copaxone patents regarding the chemical composition of the drug and the process for making it were not explicitly defined, invalidating the patent.

Judge Jones settled the matter by deciding on claim constructions for certain terms and phrases in the...
To view the full article, register now.